

## Notice of Full Year 2021 Results

**Siena, Italy, March 15, 2022** - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-based therapeutics, will announce its Full Year Results for the year ended 31 December 2021 following a Board of Director's meeting to be held on 28 March 2022.

Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief Financial Officer, and Dr. Emanuele Puca (Investor Relations) will host a virtual briefing for sell-side analysts at **9:00 ET / 14:00 BST / 15:00 CET on 1 April 2022**.

To attend the briefing, please register at the following link: <https://bit.ly/3i7VGNy>

### About Philogen

Philogen is a Swiss-Italian clinical-stage company, listed on the Italian stock exchange, engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and other ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned and has signed agreements with several major pharmaceutical companies. For more information, please visit [www.philogen.com](http://www.philogen.com) and [www.philochem.com](http://www.philochem.com).

### For more information please contact:

#### Philogen

Dr. Emanuele Puca (Investor Relations)

+41 (0) 43 544 88 00

[emanuele.puca@philogen.com](mailto:emanuele.puca@philogen.com)

#### Consilium Strategic Communications

Mary-Jane Elliott, Davide Salvi, Giulia Lasagni

[Philogen@consilium-comms.com](mailto:Philogen@consilium-comms.com)

---